Novotech

Press Releases

FDA Approves Use of the Procleix Zika Virus Assay from Hologic and Grifols to Screen the U.S. Blood

Hologic, Inc. and Grifols market-leading partners committed to blood safety - announced ย  ย that the U.S. Food and Drug Administration (FDA) has approved use of the ย Procleix Zika virus blood screening assay on the Procleix Panther system under the...

Allergan plc announces data at ASM Microbe Highlight In Vitro Antimicrobial Activity of AVYCAZ

Allergan plc committed to developing new treatment options for infectious diseases, today presented new data highlighting the in vitro activity of AVYCAZยฎ against several species of Gram-negative pathogens, including certain strains of Klebsiella pneumoniae carbapenemase (KPC)-producing Enterobacteriaceae and Pseudomonas...

Medipak Systems Open House at the new premises of Dividella AG

Dividella AG, a Medipak Systems company, welcomed guests to the two-day pharma event in its new premises in Grabs, Switzerland. As part of the extension of its capacity, Dividella has leased additional premises in the adjacent...

Quotient Clinical hosts formulation development and drug delivery seminar series

Quotient Clinical, the Translational Pharmaceutics company, is holding a series of formulation development and drug delivery seminars this June and July. The seminars will take place at major life science hubs in the UK and USA,...

Teva Pharmaceutical Inc suspends marketing for Zecuity in US

Teva Pharmaceutical Industries, Ltd. announced that it will voluntarily suspend sales, marketing and distribution of ZECUITYยฎ (sumatriptan iontophoretic transdermal system). Teva has received post-marketing reports of application site reactions described as burns and scars in patients...

FDA Accepted Charleston Laboratories, Inc. and Daiichi Sankyoโ€™s New Drug Application (NDA) for CL-108

Charleston Laboratories, Inc. and Daiichi Sankyo, Inc. announced that the U.S. FDA has accepted for review the New Drug Application (NDA) for CL-108 for the relief of moderate to severe pain while preventing or reducing the associated opioid-induced nausea...

Ziarco Pharma Ltd reports positive Phase 2a study results with ZPL-389

Ziarco Pharma Ltd a biopharmaceutical company focusing on the development of novel drugs for the treatment of inflammatory skin disorders, today announces positive, full results from its first Phase 2a proof of concept study with ZPL-389 in adults. ...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Must read

Translate ยป